Encorafenib

468 interactions 398 cited references

Also sold as: Braftovi Braftovi®

About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide

36 Contraindicated 392 Major 40 Moderate

All (468) Contraindicated (36) Major (392) Moderate (40)

Moderate

Encorafenib Atorvastatin Atorvaliq Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Axitinib Inlyta Increased OATP1B1 substrate exposure and increased risk of OATP1B1 substrate-related toxicities Details Encorafenib Docetaxel Beizray Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Docetaxel Injection Beizray Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Eluxadoline Viberzi Increased OATP1B1 substrate exposure and increased risk of OATP1B1 substrate-related toxicities Details Encorafenib Baxdrostat Reduced baxdrostat exposure and reduced efficacy of baxdrostat Details Encorafenib Cerivastatin Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Elagolix Orilissa Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Exemestane Aromasin Increased OATP1B1 substrate exposure and increased risk of OATP1B1 substrate-related toxicities Details Encorafenib Fexofenadine Allegra Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Fluvastatin Lescol Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Glecaprevir Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Glyburide DiaBeta® Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Grazoprevir Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Hydrocortisone Ala-Cort Reduced hydrocortisone exposure Details Encorafenib Irinotecan Camptosar Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Kratom Increased CYP3A substrate exposure Details Encorafenib Methotrexate Jylamvo Increased methotrexate exposure and an increased risk of methotrexate-related toxicities Details Encorafenib Momelotinib Ojjaara Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Nateglinide Starlix® Increased OATP1B1 substrate exposure and increased risk of OATP1B1 substrate-related toxicities Details Encorafenib Paclitaxel Abraxane Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Pitavastatin Livalo Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Pravastatin Pravachol Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Repaglinide Prandin® Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Revefenacin Yupelri Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Rosuvastatin Crestor Increased rosuvastatin exposure and an increased risk of rosuvastatin-related toxicities Details Encorafenib Seladelpar Increased seladelpar exposure Details Encorafenib Selexipag Uptravi Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Sofosbuvir Sovaldi Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Sulfasalazine Azulfidine Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Talazoparib Talzenna Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Tenofovir Alafenamide Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Teriflunomide Aubagio Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Topotecan Hycamtin Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Valsartan Diovan Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Voxilaprevir Increased OATP1B1 substrate exposure, increased OATP1B3 substrate exposure, increased risk of OATP1B1 substrate-related toxicities... Details Encorafenib Zavegepant Increased zavegepant exposure and increased risk of zavegepant-related toxicities Details Encorafenib Hydrocortisone Injection A-Hydrocort® Reduced hydrocortisone exposure Details Encorafenib Irinotecan Injection Camptosar Increased BCRP substrate exposure and an increased risk of BCRP substrate-related toxicities Details Encorafenib Methotrexate Injection Abitrexate® Increased methotrexate exposure and an increased risk of methotrexate-related toxicities Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.